Arena CEO Amit Munshi outlines post-Belviq ambitions for Ralinepag and Etrasimod
Having joined Arena in 2016 to turn the company around, CEO Amit Munshi negotiated the handing over of rights to the weight loss product, lorcaserin, to partner Eisai, and set about refocusing the business on its lead programs ralinepag and etrasimod. Cutting out costs of USD 100 million and raising USD 270 million from institutional investors, Arena saw its valuation rise from about USD 350 million to some USD 1.6 billion in 2017. Munshi reveals to Scrip his plans for his lead programs.